PURPOSE: Radiotherapy, combined with chemotherapy, is the treatment of choice for a large group of non-small-cell lung cancer (NSCLC) patients. Recent developments in the treatment of these patients have led to improved survival. However, the clinical TNM stage is highly inaccurate for the prediction of survival, and alternatives are lacking. The objective of this study was to develop and validate a prediction model for survival of NSCLC patients, treated with chemoradiotherapy. PATIENTS AND METHODS: The clinical data from 377 consecutive inoperable NSCLC patients, Stage I-IIIB, treated radically with chemoradiotherapy were collected. A prognostic model for 2-year survival was developed, using 2-norm support vector machines. The performance of the model was expressed as the area under the curve of the receiver operating characteristic and assessed using leave-one-out cross-validation, as well as two external data sets. RESULTS: The final multivariate model consisted of gender, World Health Organization performance status, forced expiratory volume in 1 s, number of positive lymph node stations, and gross tumor volume. The area under the curve, assessed by leave-one-out cross-validation, was 0.74, and application of the model to the external data sets yielded an area under the curve of 0.75 and 0.76. A high- and low-risk group could be clearly identified using a risk score based on the model. CONCLUSION: The multivariate model performed very well and was able to accurately predict the 2-year survival of NSCLC patients treated with chemoradiotherapy. The model could support clinicians in the treatment decision-making process.
PURPOSE: Radiotherapy, combined with chemotherapy, is the treatment of choice for a large group of non-small-cell lung cancer (NSCLC) patients. Recent developments in the treatment of these patients have led to improved survival. However, the clinical TNM stage is highly inaccurate for the prediction of survival, and alternatives are lacking. The objective of this study was to develop and validate a prediction model for survival of NSCLCpatients, treated with chemoradiotherapy. PATIENTS AND METHODS: The clinical data from 377 consecutive inoperable NSCLCpatients, Stage I-IIIB, treated radically with chemoradiotherapy were collected. A prognostic model for 2-year survival was developed, using 2-norm support vector machines. The performance of the model was expressed as the area under the curve of the receiver operating characteristic and assessed using leave-one-out cross-validation, as well as two external data sets. RESULTS: The final multivariate model consisted of gender, World Health Organization performance status, forced expiratory volume in 1 s, number of positive lymph node stations, and gross tumor volume. The area under the curve, assessed by leave-one-out cross-validation, was 0.74, and application of the model to the external data sets yielded an area under the curve of 0.75 and 0.76. A high- and low-risk group could be clearly identified using a risk score based on the model. CONCLUSION: The multivariate model performed very well and was able to accurately predict the 2-year survival of NSCLCpatients treated with chemoradiotherapy. The model could support clinicians in the treatment decision-making process.
Authors: Jie Lin; Corey A Carter; Katherine A McGlynn; Shelia H Zahm; Joel A Nations; William F Anderson; Craig D Shriver; Kangmin Zhu Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: Alyson L Mahar; Carolyn Compton; Lisa M McShane; Susan Halabi; Hisao Asamura; Ramon Rami-Porta; Patti A Groome Journal: J Thorac Oncol Date: 2015-11 Impact factor: 15.609
Authors: Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker Journal: Nat Rev Clin Oncol Date: 2012-11-20 Impact factor: 66.675
Authors: Lukas Käsmann; Maximilian Niyazi; Oliver Blanck; Christian Baues; René Baumann; Sophie Dobiasch; Chukwuka Eze; Daniel Fleischmann; Tobias Gauer; Frank A Giordano; Yvonne Goy; Jan Hausmann; Christoph Henkenberens; David Kaul; Lisa Klook; David Krug; Matthias Mäurer; Cédric M Panje; Johannes Rosenbrock; Lisa Sautter; Daniela Schmitt; Christoph Süß; Alexander H Thieme; Maike Trommer-Nestler; Sonia Ziegler; Nadja Ebert; Daniel Medenwald; Christian Ostheimer Journal: Strahlenther Onkol Date: 2017-10-13 Impact factor: 3.621
Authors: Mathilda L Bongers; Dirk de Ruysscher; Cary Oberije; Philippe Lambin; Carin A Uyl-de Groot; V M H Coupé Journal: Med Decis Making Date: 2015-03-02 Impact factor: 2.583
Authors: Erik Roelofs; Lucas Persoon; Sebastiaan Nijsten; Wolfgang Wiessler; André Dekker; Philippe Lambin Journal: Radiother Oncol Date: 2013-02-05 Impact factor: 6.280